Barclays PLC Purchases 469,401 Shares of Grifols, S.A. (NASDAQ:GRFS)

Barclays PLC increased its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 381.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 592,552 shares of the biotechnology company's stock after acquiring an additional 469,401 shares during the period. Barclays PLC's holdings in Grifols were worth $5,261,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. Hantz Financial Services Inc. acquired a new position in shares of Grifols during the second quarter worth $1,235,000. Natixis Advisors LLC increased its holdings in Grifols by 116.0% in the 2nd quarter. Natixis Advisors LLC now owns 154,053 shares of the biotechnology company's stock worth $971,000 after purchasing an additional 82,723 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in Grifols by 56.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 55,887 shares of the biotechnology company's stock valued at $352,000 after purchasing an additional 20,120 shares during the last quarter. Black Creek Investment Management Inc. boosted its stake in shares of Grifols by 7.7% during the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company's stock valued at $77,799,000 after purchasing an additional 881,155 shares in the last quarter. Finally, Highland Peak Capital LLC bought a new stake in shares of Grifols during the second quarter worth about $5,991,000.

Wall Street Analyst Weigh In

Separately, Berenberg Bank raised Grifols to a "strong-buy" rating in a research report on Tuesday, October 29th.

Grifols Stock Down 2.7 %

NASDAQ:GRFS traded down $0.21 during trading hours on Friday, hitting $7.51. 1,674,909 shares of the company traded hands, compared to its average volume of 1,829,369. The firm's 50-day simple moving average is $8.35 and its 200-day simple moving average is $8.10. The company has a market cap of $5.16 billion, a PE ratio of 7.74 and a beta of 0.43. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a one year low of $5.30 and a one year high of $12.15.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.